UNSPSC 51332854: Fluphenazine sulfoxide

This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7V73CQS9VA, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-, s-oxide, but more generally known as fluphenazine sulfoxide, which bears US NIH Compound Identifier 3036919. European Medicines Agency schedules fluphenazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07730MIG.

Most nations, for tariff purposes, schedule fluphenazine sulfoxide under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3[S+]2[O-])C(F)(F)F)CCCN4CCN(CC4)CCO.

UNSPSC 51332854 Fluphenazine sulfoxide is a Commodity code that shows minimal alignment with current state and local procurement activity. The single recent opportunity tagged under this code — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 — solicits naloxone and safe drug deactivation systems for community health delivery, a pharmaceutical product category that does not correspond to fluphenazine sulfoxide, an antipsychotic medication. The mismatch suggests either a tagging error in the county's procurement system or that this code does not capture the work state and local buyers are actually conducting under it.

Seminole County's opportunity calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building in Sanford, Florida. The IFB closing date was July 26, 2023, with vendors required to submit unit pricing, drug-free workplace certification, E-Verify compliance, and specified insurance coverage including workers' compensation and commercial general liability. The two-year contract with a one-year renewal option carried potential FEMA funding and federal compliance obligations. Beyond this single solicitation, the code shows no other recent state or local opportunities in the data provided, limiting the ability to characterize issuing-body mix, geographic spread, or recurring procurement patterns under the fluphenazine sulfoxide classification.